RecruitingPhase 2Phase 3NCT05636826

Olive Leaf Extracts in the Control of Hypertension

Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Cardiovascular Risk Factors:Hypertension


Sponsor

University of Monastir

Enrollment

500 participants

Start Date

Dec 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). Patients over 18 years of age with: Arterial hypertension (hypertension).


Eligibility

Min Age: 18 YearsMax Age: 95 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether taking olive leaf extract — a natural supplement derived from olive tree leaves — can help lower blood pressure in people diagnosed with hypertension (high blood pressure). Compounds found in olive leaves, such as oleuropein, have shown some potential anti-inflammatory and blood vessel–relaxing effects in prior research. **You may be eligible if...** - You are over 18 years old - You have a confirmed diagnosis of high blood pressure (hypertension) - You are willing to take the supplement as directed and attend follow-up visits **You may NOT be eligible if...** - You do not have high blood pressure - You have known allergies to olive leaf products - You are unable to follow the study schedule (note: the study lists minimal exclusion criteria) This is a low-intervention study exploring a natural supplement option for blood pressure management. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGatherolive-drug

The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.

DRUGPlacebo Atherolive

The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.


Locations(1)

University Hospital Fattouma Bourguiba Monastir

Monastir, Tunisia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05636826


Related Trials